Europe Blood Screening Market Set to Witness an Uptick during 2019 to 2025

Posted by Mrudula Anil Karmarkar on February 9th, 2022

The Europe blood screening market size is expected to reach USD 1.17 billion by 2025 according to a new report by Grand View Research, Inc. The market is expected to record a CAGR of 7.7% during the forecast period. Increasing number of blood transfusion processes performed along with stringent regulations in Europe mandating screening tests, such as NAT for testing HIV, HBV, and HCV, is contributing to the market growth.

Moreover, growth in the overall number of complex surgeries that require a large amount of blood and blood products along with rising cases of road accidents is expected to drive the market further. Additionally, import of products through contract agreements and development in the product technology by manufacturers of blood screening reagents and instruments are contributing to market expansion in the region.

For example, DiaSystem Scandinavia AB signed a distribution agreement with SNIBE, an Asian immunology test producer that focuses on immunoassay analyzers based on CLIA technology. DiaSystem specializes in the production and supply of reagents used in chemistry and immunoturbidimetry. This agreement has provided the former company with automated chemiluminescence instrument delivering a complete analytical system in areas, such as thyroid, renal function, hepatitis, and hepatic fibrosis.

The rising number of blood transfusion procedures is expected to be the major factor boosting the market growth. The rise in the number of complex surgeries performed, such as chemotherapy, heart surgery, and organ transplant, which require a large number of blood samples is also likely to have a positive impact on the market. Moreover, increasing awareness about safe blood transfusion and rising incidence of infectious diseases are projected to augment the market development in the coming years. Stringent government regulations regarding the screening of all donors and donated blood for patient safety are anticipated to further propel the market growth.

To Request Sample Copy of this report, click the link:

https://www.grandviewresearch.com/industry-analysis/europe-blood-screening-market/request/rs1

Such guidelines regarding the transfusion services provide a regulatory framework for the manufacturers of blood transfusion reagents. European countries have mandated blood screening for HIV, HBV, HCV, parvovirus 19, and other viruses. The blood transfusion services in Germany are regulated by the International Red Cross, the Code of International Society of Blood Transfusion, and the German Transfusion Act.

In France, the French Blood Establishment (EFS) regulates the collection, preparation, testing, and distribution of labile blood products. In Italy, the National Blood Centre (NBC), a division of health ministry, is responsible for the coordination of technical and scientific control of the blood system.

Further key findings from the study suggest:

• NAT led the technology segment in 2017 owing to a regulatory obligation for mandatory NAT screening for all blood donations.
• On the basis of product, reagents led the Europe blood screening market in 2017
• Germany held a majority of the market share in 2017 due to large number of blood donors.
• Moreover, stringent regulations in the country for screening of donations also contributed to its growth. The Paul-Ehrlich-Institut, a medical regulatory body in Germany, mandates NAT testing for HCV and HIV for all blood donations.
• Roche Diagnostics; Bio-Rad Laboratories, Inc.; Siemens Healthcare GmbH; Grifols, S.A.; Becton, Dickinson and Company; Agilent Technologies; Thermo Fisher Scientific, Inc.; and Danaher Corp. are some of the key companies operating in this market.

Some of the major companies in the market are Roche Diagnostics; Bio-Rad Laboratories, Inc.; Siemens Healthcare GMBH; Grifols, S.A.; Becton, Dickinson, and Company; Agilent Technologies; Thermo Fisher Scientific, Inc.; and Danaher Corp. Most of the manufacturers focus on new technology launch and M&A activities for business expansion.

For instance, Grifols acquired Hologic’s unit, which is engaged in the manufacturing and R&D of assays and instruments based on NAT technology for donor screening. The sales of Procleix NAT Solutions from this acquisition became the leading source of revenue for the diagnostic division.

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.